Figure 1.

BoHV-4 gB constructs design. A) Schematic representation (not to scale) of BoHV-4 gB ORF; in grey is represented the putative protease site and in red the transmembrane domain. B) BoHV-4 gB annotated sequence with deduced amino acidic sequence, from the ATG to stop site. In grey is underlined the putative protease site (RQKRS) and in red the transmembrane domain. C) Diagram (not to scale) showing the pWPI/gBFc vector containing: the human elongation factor 1α (PeF1 α) promoter, the chimeric gB ORF ectodomain (gB) (1-720aa), the protease site is evidenced in grey, fused with the murine Fc (in sky blue), then an IRES and the EGFP ORF (in green). Diagram (not to scale) showing the pWPI/gBtruncatedFc vector containing: the human elongation factor 1α (PeF1 α) promoter, the chimeric gB ORF ectodomain (1-420aa), fused with the murine Fc (in sky blue), then an IRES and the EGFP ORF. Diagram (not to scale) showing the pWPI/gBgD106 vector containing: the human elongation factor 1α (PeF1 α) promoter, the chimeric gB ORF ectodomain (1-720aa), the protease site is evidenced in grey, fused with the gD106 tag (in yellow), then an IRES and the EGFP ORF. Diagram (not to scale) showing the pWPI/gBtruncated-gD106 vector containing: the human elongation factor 1α (PeF1 α) promoter, the chimeric gB ORF ectodomain (1-420aa), fused with the gD106 tag (in yellow), then an IRES and the EGFP ORF.

Franceschi et al. BMC Veterinary Research 2013 9:6   doi:10.1186/1746-6148-9-6
Download authors' original image